Absci Corporation (ABSI)

Compare

3.8650

+0.1700

(+4.60%)

As of 1:29:42 PM EST. Market Open.

Absci highlights progress, updates across proprietary pipeline

Absci (ABSI) Corporation announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci’s AI Integrated Drug Creation platform. ABS-201: ABS-201 has potential to offer a safe option as compared to current standard of care, Anticipate initiation of Phase 1 clinical trial in 1H 2026. ABS-101: Anticipate initiation of Phase 1 clinical trial in 1H 2025; ABS-301: For this program, Absci has optimized an antibody le

TipRanks 3 days ago

ABSI
+4.60%
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day

Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia Leading AI platform demonstrated breakthrough in successful de novo design of antibody targeting previously difficult-to-drug epitope in the HIV “caldera” region VANCOUVER, Wash. and NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced updates and progress across its interna

GlobeNewswire 4 days ago

ABSI
+4.60%
Absci Corporation (NASDAQ:ABSI) is favoured by institutional owners who hold 56% of the company

Key Insights Institutions' substantial holdings in Absci implies that they have significant influence over the...

Simply Wall St. 10 days ago

ABSI
+4.60%
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY. Absci’s Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled “The Promise of AI in Drug Development” on Thursday, December 5th at 2:00 p.m. Eastern Time. Interested parties may contact thei

GlobeNewswire 25 days ago

ABSI
+4.60%
Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges

Absci Corp (ABSI) showcases promising collaborations and a robust pipeline amid rising R&D expenses and revenue challenges.

GuruFocus.com last month

ABSI
+4.60%
Q3 2024 Absci Corp Earnings Call

Q3 2024 Absci Corp Earnings Call

Thomson Reuters StreetEvents last month

ABSI
+4.60%
AZN
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of -26.32% and 4.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ABSI
+4.60%
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody using generative AI VANCOUVER, Wash. and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2024. "The recent progress we have made across

GlobeNewswire last month

ABSI
+4.60%
Absci to Host R&D Day on December 12, 2024

VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City. The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci’s leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Easte

GlobeNewswire last month

ABSI
+4.60%
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibodyVANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ: TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform,

GlobeNewswire last month

ABSI
+4.60%
TWST
Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. Truist Securities BioPharma Symposium (New York, NY)Hosting 1x1 meetings on Thursday, November 7 Guggenheim Securities Inaugural Healthcare Innovation Conference (Boston, MA)Fireside chat on Monday, November 11 at 10:00 a.m. Eastern Time / 7:00 a.m. Pac

GlobeNewswire last month

ABSI
+4.60%
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating r

GlobeNewswire 2 months ago

ABSI
+4.60%
Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire

We recently compiled a list of the 11 Penny Stocks That Will Make You A Millionaire. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other penny stocks. Why Should You Invest in Penny Stocks? Penny stocks are often overlooked by most investors. These are the smallest […]

Insider Monkey 3 months ago

ABSI
+4.60%
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite falling stocks.

Motley Fool 3 months ago

TEM

ABSI
+4.60%
Absci Second Quarter 2024 Earnings: Misses Expectations

Absci ( NASDAQ:ABSI ) Second Quarter 2024 Results Key Financial Results Net loss: US$24.8m (loss narrowed by 41% from...

Simply Wall St. 3 months ago

ABSI
+4.60%
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of -15.79% and 37.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

ABSI
+4.60%
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development Entered into collaboration with Memorial Sloan Kettering Cancer Center to co-develop up to six novel oncology therapeutics VANCOUVER, Wash. and NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended June 30, 2

GlobeNewswire 3 months ago

ABSI
+4.60%
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of -17.65% and 58.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

ABSI
+4.60%
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeuticsVANCOUVER, Wash. and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Today, Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up

GlobeNewswire 4 months ago

ABSI
+4.60%
Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now?

We recently compiled a list of the 10 Micro Cap Stocks That Will Skyrocket. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other micro cap stocks. One of the more well known quotes of Warren Buffett is “Only buy something that you’d be perfectly happy […]

Insider Monkey 4 months ago

ABSI
+4.60%

Performance Overview

Return	ABSI	S&P 500
YTD	-7.98%	+27.54%
1-Year	+41.58%	+28.91%
3-Year	-62.03%	+29.16%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Absci Corporation (ABSI)

Absci highlights progress, updates across proprietary pipeline

Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day

Absci Corporation (NASDAQ:ABSI) is favoured by institutional owners who hold 56% of the company

Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference

Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges

Q3 2024 Absci Corp Earnings Call

Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Absci to Host R&D Day on December 12, 2024

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Absci to Participate in Upcoming Investor Conferences

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Absci Second Quarter 2024 Earnings: Misses Expectations

Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now?

Performance Overview